Cures Start Here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Careers Start Here.
The Greenberg group is part of a SU2C/AACR-funded multicenter “Dream Team” that is performing a T cell therapy trial for patients with non-small cell lung cancer or mesothelioma. This trial is testing the therapeutic activity of autologous CD8+ T cells, derived from either naïve or central memory T cell precursors, transduced to express a high affinity, HLA-A2-restricted, WT1-specific TCR developed in the our lab. This TCR is also being evaluated in a similar trial design for therapy of acute myelogenous leukemia (AML), a setting in which we have shown that WT-1 specific CD8 T cells can prevent leukemic relapse in at least a fraction of patients. We are also working to identify epitopes in WT1 and other antigens that are commonly found on AML and other malignancies and restricted to Class I MHC alleles beyond HLA-A2, so that TCRs can be isolated and high avidity CD8+ T cells generated to treat a much broader range of patients.
We are looking for a highly motivated individual to support the development of immunotherapy for cancer. The successful candidate will utilize a variety of cutting-edge cellular and molecular techniques to analyze T cell immunity to cancer. The technician will be closely involved in the preclinical development of new TCR-based therapies and their translation into clinical trials. The candidate should be capable of maintaining detailed laboratory records, analyzing data, and reporting experimental results.
Assist in the design, implementation and interpretation of experiments involving human T lymphocytes engineered to target tumor cells. These studies are specifically aimed at identifying ways to increase the therapeutic activity of tumor-reactive T lymphocytes.